Could iPSCs Enable "Off-the-Shelf" Cell Therapy?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31199910.
- Also identified by DOI 10.1016/j.cell.2019.05.043.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An "off-the-shelf" cell therapy derived from induced pluripotent stem cells (iPSCs) has entered clinical trials in the United States. Other companies are following suit, harnessing iPSCs' self-renewal ability to manufacture cell therapies that don't require customization for each patient. But some experts aren't sure such therapies are a good idea.
Medical subject headings
- Cell Differentiation
- Cell- and Tissue-Based Therapy
- Induced Pluripotent Stem Cells